Letter to the Editor

Kittleson, Mark D.; Rishniw, Mark; Pion, Paul D.; Kass, Philip H.

doi:10.1111/j.1939-1676.2009.0361.x

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unblinded conditions and lack of randomisation lead to an overwhelming risk for systematic errors in case series addressing treatment effects, most notably with retrospective case series. Therefore, the results from these case series are outranked by the results from the two placebo–controlled clinical trials of enalapril (Kittleson and others 2009).…”

Section: Therapy Of Asymptomatic Mrmentioning

confidence: 99%

An update on treatment and prognostic indicators in canine myxomatous mitral valve disease

Häggström

Höglund

Borgarelli

2009

J of Small Animal Practice

View full text Add to dashboard Cite

Mitral regurgitation caused by myxomatous mitral valve disease is the most common cause for congestive heart failure and cardiac-related mortality in dogs. Typically, it takes several years for the disease to progress from mild, clinically silent myxomatous mitral valve disease to severe disease with signs of congestive heart failure. A proportion of dogs will never progress into congestive heart failure before they die from other causes or old age. Some variables have been shown to be predictive of onset of congestive heart failure and they might be useful to identify dogs that need more frequent monitoring and eventually treatment. Results from several controlled clinical trials are available concerning medical treatment of dogs with myxomatous mitral valve disease with or without congestive heart failure. These trials provide estimates of treatment effects and also allow identification of other variables with prognostic value for the outcome after the onset of congestive heart failure. Use of prognostic variables together with qualitative and quantitative results from clinical drug trials may aid the clinician and owner to plan and decide on optimal management of the myxomatous mitral valve disease dog. The purpose of this article is to review the current knowledge of prognostic variables and therapy for this common condition in dogs.

show abstract

Section: Therapy Of Asymptomatic Mrmentioning

confidence: 99%

An update on treatment and prognostic indicators in canine myxomatous mitral valve disease

Häggström

Höglund

Borgarelli

2009

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

Canine Degenerative Myxomatous Mitral Valve Disease: Natural History, Clinical Presentation and Therapy

Borgarelli

Häggström

2010

Veterinary Clinics of North America: Small Animal Practice

143

101

View full text Add to dashboard Cite

Role of Medical Therapy in Chronic Mitral Regurgitation

Meel¹

2020

The Current Perspectives on Coronary Artery Bypass Grafting

View full text Add to dashboard Cite

Mitral regurgitation is one of the most commonly encountered valvular heart diseases in both the developing and the developed world. From various studies, it is known that chronic mitral regurgitation is associated with progressive left ventricular dysfunction, and eventually death if left untreated. This disease has a long silent period before symptoms manifest. During this latent period, left ventricular function progressively deteriorates and results in poor outcomes for patients even if surgery is performed. A few studies have evaluated the role of medical therapy in patients with chronic mitral regurgitation. This chapter will provide an overview of the use of medical therapy in chronic mitral regurgitation.

show abstract

Letter to the Editor

Cited by 3 publications

References 8 publications

An update on treatment and prognostic indicators in canine myxomatous mitral valve disease

An update on treatment and prognostic indicators in canine myxomatous mitral valve disease

Canine Degenerative Myxomatous Mitral Valve Disease: Natural History, Clinical Presentation and Therapy

Role of Medical Therapy in Chronic Mitral Regurgitation

Contact Info

Product

Resources

About